Reaktionsgleichung
[F:1][C:2]1[CH:11]=[C:10]2[C:5]([CH:6]=[CH:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[CH2:12][N:13]1[C:21]2[C:16](=[N:17][CH:18]=[C:19]([C:22](=O)[CH3:23])[N:20]=2)[N:15]=[N:14]1.[NH2:25][N:26]1[CH2:30][C:29](=[O:31])[NH:28][C:27]1=[O:32]>>[F:1][C:2]1[CH:11]=[C:10]2[C:5]([CH:6]=[CH:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[CH2:12][N:13]1[C:21]2[C:16](=[N:17][CH:18]=[C:19](/[C:22](=[N:25]/[N:26]3[CH2:30][C:29](=[O:31])[NH:28][C:27]3=[O:32])/[CH3:23])[N:20]=2)[N:15]=[N:14]1Komponenten
3
Versuchsvorschrift
The title compound (18.0 mg, 66%) was synthesized from 1-[3-(7-fluoro-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-ethanone (20.0 mg, 0.06 mmol) and 1-amino-imidazolidine-2,4-dione (28.2 mg, 0.19 mmol) using the same procedure as described in the synthesis of example 72. 1H-NMR (400 MHz, DMSO-d6) δ ppm 11.45 (bs, 1H), 9.41 (s, 1H), 8.93 (dd, 1H), 8.42 (d, 1H), 8.21 (d, 1H), 7.83 (d, 1H), 7.54 (dd, 1H), 6.26 (s, 2H), 4.56 (s, 2H), 2.45 (s, 3H). LCMS (method B): [MH]+=420, tR=1.95 min.
Aufarbeitung
- customas described in the synthesis of example 72
Quellen und Nachweise
- ORD-Eintrag
- ord-85731c5585c14b7f9e962c9c7392199a
- Quelldatensatz
- uspto-grants-2013_07
- Patentnummer
- US08497368B2
Verknüpfte Notizen
Wird geladen…